Catalyst Wire Dossier Catalyst Wire Dossier

Fluticasone propionate / salmeterol xinafoate inhalation aerosol (HFA)

fluticasone propionate / salmeterol · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Fluticasone propionate / salmeterol xinafoate inhalation aerosol (HFA), covering 2017-06-16 to 2017-06-16. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma [Phase 4]

See pricing